Taxis Pharmaceuticals INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersMonmouth Junction, NJ
SAM.gov UEIC2NWS2FZS5F5
TAXIS Pharmaceuticals is developing investigational therapeutic drugs to combat antimicrobial resistance by targeting bacterial cellular mechanisms. The company's lead candidate, TXA709, is an oral FtsZ inhibitor designed to target bacterial cell division protein and disrupt bacterial cell walls, and has completed Phase I trials. TXA709 has been designated a Qualified Infectious Disease Product (QIDP) by FDA.
Summarized from the company’s own website
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Taxis Pharmaceuticals INC | Monmouth Junction | NJ | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.